Skip to content
Open access

High levels of MCP-1 in menopause and their relationship with components of the metabolic syndrome.

2026 · Gaceta Médica de México · Vol 162 1, pp. 67-72 · 0 citations
Medicine

Abstract

Background

The menopause stage involves a significant reduction in circulating estrogen levels, resulting in notable changes to the cardiovascular, metabolic, bone, and immune systems. Monocyte chemoattractant protein-1 (MCP-1) is strongly associated with cardiovascular diseases and obesity. However, it is crucial to establish and clarify the relationship between MCP-1 and metabolic parameters in postmenopausal women.

Objective

The objective of this study was to assess the relationship between MCP-1 concentrations and various anthropometric and metabolic markers in premenopausal and postmenopausal women. MATERIAL AND

Methods

A case-control study, including 82 women (41 in postmenopausal stage, and 41 in premenopausal stage), was matched by body mass index (BMI). Insulin, estradiol, and C-reactive protein (CRP) levels were quantified by chemiluminescence and MCP-1 by enzyme-linked immunosorbent assays.

Results

Age was 46.3 ± 2.4 years in premenopausal women and 55.6 ± 5.1 years in postmenopausal women. The MCP-1 level was higher in postmenopausal than premenopausal women (28.7 ± 10.4 vs. 21.3 ± 16.3 pg/mL, p = 0.04). The MCP-1 correlated with BMI (r = 0.39, p = 0.0001), waist circumference (r = 0.34, p = 0.002), CRP (r = 0.33, p = 0.03), high-density lipoprotein cholesterol (r = -0.28, p = 0.02), and visceral adipose tissue (VAT) (r = 0.38, p = 0.0001). Multiple stepwise regression analysis showed that VAT influenced the MCP-1 level.

Conclusion

Menopausal status influences MCP-1 concentrations; however, the relationship of MCP-1 with VAT favors the activation of inflammatory mechanisms, outweighing the effects of hormonal status.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.